This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Zai Lab Limited
11/5/2026
Ladies and gentlemen, thank you for standing by and welcome to Zai Lab's third quarter 2026 Financial Results Conference call. At this time, all participants are in the listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Christine Chiou Senior Vice President of Investor Relations. Please go ahead. Thank you, operator.
Hello and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Scilabs founder, CEO, and chairperson. She will be joined by Dr. Rafael Amado, President and Head of Global Research and Development, and Dr. Yajing Chen, Chief Financial Officer. Dr. Shan He, our Chief Business Officer, and Dr. Yijie Wang, our operating partner, will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. We will also refer to adjusted loss from operations, which is a non-GAAP financial measure, please refer to our earnings release furnished with the SEC on November 5th, 2026 for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.
Thanks, Christine. Good morning and good evening, everyone. We're entering one of the most important periods in Zai Lab's history. I founded Zai Lab to discover and develop innovative medicines for patients around the world. We have spent years building the talent, scientific capabilities, and infrastructure to make that possible. With Zosie advancing toward a potential US DLA submission next year, that vision is within our reach. Our first-line asthma data strengthened our confidence that Zosie can become the ADC backbone in small cell lung cancer. We are advancing the ZO-CiO doublet into a global phase III study and building on it through our T-cell engager collaborations with Amgen and BIA. The next two years are pivotal. By year end, we expect three registrational studies underway across small cell lung cancer and neuroendocrine carcinomas. In 2027, we anticipate two registrational readouts and our first potential U.S. DLA submission, positioning us for a U.S. launch as early as 2028. This would be a defining achievement for our company. Our recent $250 million financing further strengthens our ability to deliver on the plan. Our ambition extends well beyond Zosie. Next week, we'll present The first clinical data for CL1503 are internally developed bispecific for atopic dermatitis. We also expect three additional oncology and immunology assets in clinical development next year. Meanwhile, we continued to strengthen our China commercial business. Net product revenue grew 2% sequentially, and our China business remained profitable. This performance is consistent with the stabilization we outlined on our second quarter call. We remain on track with that trajectory and continue to expect a return to year-over-year product revenue growth in 2027. I'm very proud of what our team has accomplished, but our most important achievements are still ahead of us, and I look forward to updating you over the next year. With that, I'll turn the call over to Rafael. Thank you.
You're reading a preview of the ZLAB Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing